Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 2.67% and Operating profit at -19.19% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 12.29% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 2.67% and Operating profit at -19.19% over the last 5 years
3
With a fall in Operating Profit of -36.28%, the company declared Very Negative results in Mar 25
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,145 Million (Mid Cap)
NA (Loss Making)
NA
0.19%
1.35
-1.48%
2.17
Revenue and Profits:
Net Sales:
1,801 Million
(Quarterly Results - Jun 2025)
Net Profit:
-32 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.78%
0%
-11.78%
6 Months
-14.33%
0%
-14.33%
1 Year
-18.07%
0%
-18.07%
2 Years
-38.49%
0%
-38.49%
3 Years
32.29%
0%
32.29%
4 Years
9.2%
0%
9.2%
5 Years
17.42%
0%
17.42%
Shanghai Runda Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.67%
EBIT Growth (5y)
-19.19%
EBIT to Interest (avg)
2.47
Debt to EBITDA (avg)
5.08
Net Debt to Equity (avg)
1.29
Sales to Capital Employed (avg)
0.80
Tax Ratio
100.00%
Dividend Payout Ratio
32.75%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.23%
ROE (avg)
12.29%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.17
EV to EBIT
67.88
EV to EBITDA
23.37
EV to Capital Employed
1.50
EV to Sales
1.95
PEG Ratio
NA
Dividend Yield
0.19%
ROCE (Latest)
2.21%
ROE (Latest)
-1.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,801.30
1,654.90
8.85%
Operating Profit (PBDIT) excl Other Income
125.00
82.30
51.88%
Interest
72.30
68.10
6.17%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-31.60
-67.90
53.46%
Operating Profit Margin (Excl OI)
15.60%
-8.80%
2.44%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 8.85% vs -22.16% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 53.46% vs -243.25% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
8,270.80
9,100.30
-9.12%
Operating Profit (PBDIT) excl Other Income
968.00
1,113.70
-13.08%
Interest
320.80
342.80
-6.42%
Exceptional Items
-33.40
-23.60
-41.53%
Consolidate Net Profit
189.50
442.60
-57.18%
Operating Profit Margin (Excl OI)
66.00%
78.30%
-1.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -9.12% vs -12.97% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -57.18% vs -32.44% in Dec 2023
About Shanghai Runda Medical Technology Co., Ltd. 
Shanghai Runda Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






